Small RNA Sequencing Identifies a Six-MicroRNA Signature Enabling Classification of Brain Metastases According to their Origin

Roskova, Ivana; Večeřa, Marek; Radová, Lenka; Trachtová, Karolína; Siegl, František; Hermanová, Markéta; Hendrych, Michal; Křen, Leoš; Vybíhal, Václav; Valekova, Hana; Kašparová, Petra; Kolouskova, Ivana; Kazda, Tomáš; Slabý, Ondřej; Jančálek, Radim; Šána, Jiří; Smrčka, Martin

doi:10.21873/cgp.20361

Cited by 6 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lowest sensitivity was observed in BML, which corresponds with high heterogeneity of histological types (23). These ndings and identi ed miRNA pro les are consistent with the results of Roskova et al (10). However, biopsy and subsequent histopathological examination is not always indicated due to the fragility of cancer patients and the high invasiveness of the surgical procedure or the BM localization.…”

Section: Discussionsupporting

confidence: 88%

“…The RNA input was 100 ng for tissue and 5 µl for plasma and CSF. The preparation and cDNA libraries quantity and quality control were described in detail earlier (10). Subsequently, libraries were normalized and pooled in equimolar ratio using online weight to molar quantity converter.…”

Section: Library Preparation Pooling and Sequencingmentioning

confidence: 99%

“…Speci cally, plasma levels of miR-21, miR-128, and miR-342-3p were observed to be signi cantly altered in GBM patients compared to non-tumor controls (9). Diagnostic potential of tissue miRNAs for brain metastases have been investigated recently (10). Nevertheless, there is a need for further research to identify accurate and reliable biomarkers for the early detection of brain metastases.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Circulating MicroRNAs Do Not Provide a Diagnostic Benefit Over Tissue Biopsy in Patients With Brain Metastases

Ruckova,

Tukmachi,

Vecera

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Brain metastases (BMs) are frequent and devastating complications of systemic malignancies, necessitating accurate diagnosis and origin identification for effective treatment strategies. Invasive biopsies are currently required for definitive diagnosis, highlighting the need for less invasive diagnostic approaches and robust biomarkers. Circulating microRNAs (miRNAs) have demonstrated potential as sensitive and specific diagnostic biomarkers in various cancers. Thus, our objective was to identify and compare miRNA profiles in BM tissue, cerebrospinal fluid (CSF), and plasma, with a specific focus on liquid biopsies for diagnostic purposes. Methods: Total RNA enriched for miRNAs was isolated from histopathologically confirmed BM tissues (n=30), corresponding plasma samples (n=30), and CSF samples (n=27) obtained from patients with diverse BM types. Small RNA sequencing was employed for miRNA expression profiling. Results: Significantly differentially expressed miRNAs were observed in BM tissues, enabling the differentiation of primary origins, particularly breast, colorectal, renal cell carcinoma, and melanoma metastases. The heterogeneity observed in lung carcinomas also manifested in the corresponding BMs, posing challenges in accurate discrimination from other BMs. While tissue-specific miRNA signatures exhibited the highest precision, our findings suggest low diagnostic potential of circulating miRNAs in CSF and blood plasma for BM patients. Conclusions: Our study represents the first analysis of miRNA expression/levels in a unique set of three biological materials (tissue, blood plasma, CSF) obtained from the same BM patients using small RNA sequencing. The presented results underscore the importance of investigating aberrant miRNA expression/levels in BMs and highlight the low diagnostic utility of circulating miRNAs in patients with BMs.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Library Preparation Pooling and Sequencingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating MicroRNAs Do Not Provide a Diagnostic Benefit Over Tissue Biopsy in Patients With Brain Metastases

Ruckova,

Tukmachi,

Vecera

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…This study identifies miR-202–3p as a critical regulator of brain metastasis and highlights the miR-202–3p/MMP-1 axis as a potential prognostic and therapeutic target. Roskova et al analyzed miRNA expression in 71 fresh frozen histopathologically confirmed BM tissues originating from five common cancer types (lung, breast, renal cell carcinoma, colorectal carcinoma, and melanoma) [ 46 ]. MiRNA sequencing and subsequent validation by RT-qPCR were used to identify 373 miRNAs with significantly different expression across the five BM groups.…”

Section: Mirnas As Therapeuticsmentioning

confidence: 99%

MiRNAs as new potential biomarkers and therapeutic targets in brain metastasis

Beylerli,

Shi,

Begliarzade

et al. 2024

Non-coding RNA Research

View full text Add to dashboard Cite

“…Roskova et al studied microRNAs expression in brain metastases arising from different origins, and they found that there is a significantly different expression of six microRNAs in five groups of brain metastases, including brain metastases with origin in melanomas, renal cell carcinomas, breast carcinomas, lung carcinomas, colorectal carcinomas [ 38 ]. These microRNAs include microRNA-141-3p, microRNA-141-5p, microRNA-146a-5p, microRNA-194-5p, microRNA-200b-3p, microRNA-365b-5p [ 38 ].…”

Section: Reviewmentioning

confidence: 99%

Advances in Brain Metastases Diagnosis: Non-coding RNAs As Potential Biomarkers

Eraky¹

2023

Cureus

View full text Add to dashboard Cite

Brain metastasis is considered the most common brain tumor. They arise from different primary cancers. The most common primary tumors giving brain metastases include breast, colorectal, lung, melanoma, and renal cancer. Depending only on history, physical examination, and conventional imaging modalities makes brain tumors diagnosis difficult. Rapid and non-invasive promising modalities could diagnose and differentiate between different brain metastases without exposing the patients to unnecessary brain surgeries for biopsies. One of these promising modalities is non-coding RNAs (ncRNAs). NcRNAs can determine brain metastases' prognosis, chemoresistance, and radioresistance. It also helps us to understand the pathophysiology of brain metastases development.Additionally, ncRNAs may work as potential therapeutic targets for brain metastases treatment and prevention. Herein, we present deregulated ncRNAs in different brain metastases, including microRNAs and long non-coding RNAs (lncRNAs), such as gastric adenocarcinoma, colorectal, breast, melanoma, lung, and prostate cancer. Additionally, we focus on serum and cerebrospinal fluid (CSF) expression of these ncRNAs in patients with brain metastases compared to patients with primary tumors. Moreover, we discuss the role of ncRNAs in modulating the immune response in the brain microenvironment. More clinical studies are encouraged to assess the specificity and sensitivity of these ncRNAs.

show abstract

Small RNA Sequencing Identifies a Six-MicroRNA Signature Enabling Classification of Brain Metastases According to their Origin

Cited by 6 publications

References 32 publications

Circulating MicroRNAs Do Not Provide a Diagnostic Benefit Over Tissue Biopsy in Patients With Brain Metastases

Circulating MicroRNAs Do Not Provide a Diagnostic Benefit Over Tissue Biopsy in Patients With Brain Metastases

MiRNAs as new potential biomarkers and therapeutic targets in brain metastasis

Advances in Brain Metastases Diagnosis: Non-coding RNAs As Potential Biomarkers

Contact Info

Product

Resources

About